Service d’Hématologie Biologique Hôpital Tenon, APHP, Paris, France Group Thrombosis and Cancer Cancer Biology and Therapeutics Centre de Recherche Saint-Antoine.

Slides:



Advertisements
Similar presentations
1 Severe morbidity among HIV- infected patients : a comparison between a Brazilian and a French clinic based observational cohort FIOCRUZ: Prof B Grinsztejn.
Advertisements

Long Term Follow-Up After Imatinib Cessation for Patients in Deep Molecular Response: The Update Results of the STIM1 Study1 Preliminary Report of the.
 Try to determine causes and risk factors for disease by drawing connections between behaviors or exposures and diseases through observation alone.
EFFICACY AND SAFETY OF RECOMBINANT HUMAN ACTIVATED PROTEIN C FOR SEVERE SEPSIS (PROWESS) GORDONR. BERNARD, M.D. et al. The New England Journal of Medicine.
Reporter: CR 吳嘉芸 Supervisor: VS 邱宗傑. Reporter: CR 吳嘉芸 Supervisor: VS 邱宗傑.
The DASH Study Patrick Leonberger MSIV BGSMC Nov 8, 2013.
Departments - Surgery - Gerontology and Geriatrics Department of SurgeryDepartment of Gerontology & Geriatrics Prof. dr. C.J.H. van de VeldeProf. dr. R.G.J.
Analysis of risk factors predicting time to development of brain metastases presented at the 44 th Annual ASCO Meeting, June , McCormick.
1.A 33 year old female patient admitted to the ICU with confirmed pulmonary embolism. It was noted that she had elevated serum troponin level. Does this.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Neoadjuvant Chemotherapy in Ovarian Cancer Key issues in trial design.
EINSTEIN DVT and EINSTEIN PE Pooled Analysis
C-Reactive Protein: a Prognosis Factor for Septic Patients Systematic Review and Meta-analysis Introduction to Medicine – 1 st Semester Class 4, First.
Study Design / Data: Case-Control, Descriptives Basic Medical Statistics Course: Module C October 2010 Wilma Heemsbergen
Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.
Evaluating the Performance of a Previously Reported Risk Score to Predict Venous Thromboembolism: A VERITY Registry Study Denise O'Shaughnessy, Peter Rose,
Diabetes mellitus and the incidence and time to onset of oxaliplatin-induced peripheral sensory neuropathy in patients with colorectal cancer: A pooled.
Definition of oxaliplatin sensitivity in pts with advanced colorectal cancer previously treated with oxaliplatin-based therapy A. de Gramont, B. Chibaudel,
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer Agnelli G et al. N Engl J Med 2012;366(7): George D et al. Proc.
EPIB-591 Screening Jean-François Boivin 29 September
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Objectives Abstract Background Materials & Methods References 1.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of.
DEFINING THE DURATION OF ANTICOAGULATION. HOW LONG TO TREAT A DVT?
The Role of Thromboprophylaxis in Elective Spinal Surgery The Role of Thromboprophylaxis in Elective Spinal Surgery VA Elwell, N Koo Ng, D Horner & D Peterson.
Insert Program or Hospital Logo Introduction Melanoma is notoriously resistant to chemotherapy. While surgical resection and adjuvant chemotherapy can.
Complicanze trombotiche nel mieloma multiplo Mauro Berrettini S.C. Medicina Generale-DH Oncologico Ospedale di Orvieto Mediterranean School of Oncology.
THE ROLE OF D-DIMER AT SCREENING VENOUS THROMBOSIS IN ADVANCED CANCER PATIENTS Panagiotis Heras (1), Theodosis Andrianopoulos (1), Ioannis Tsiverdis (1),
Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique Hôpitaux de Paris, France. Groupe de Thrombose Equipe de recherche ER2UPMC Interactions.
Therapeutic Significance of D-dimer Cut-off Level of more than 3 µg/ml in Colorectal Cancer Patients Treated with Standard Chemotherapy plus Bevacizumab.
ST CATHERINE’S HOSPICE Primary thromboprophylaxis in advanced disease MJ Johnson.
1 SNDA Gemzar plus Carboplatin Treatment of Late Relapsing Ovarian Cancer.
EVALUATION OF CONVENTIONAL V. INTENSIVE BLOOD GLUCOSE CONTROL Glycemic Control in Critically Ill Patients DANELLE BLUME UNIVERSITY OF GEORGIA COLLEGE OF.
Annual Report 2003 Power Point Presentation. Mechanics of merging data.
Incidence of hospitalisations in both groups Incidence of documented infections Abstract Problem statement: Patients on cancer chemotherapy are at substantial.
INCREASED EXPRESSION OF PROTEIN KINASE CK2  SUBUNIT IN HUMAN GASTRIC CARCINOMA Kai-Yuan Lin 1 and Yih-Huei Uen 1,2,3 1 Department of Medical Research,
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Aubert RE et al. ASCO 2009; Abstract CRA508. (Oral Presentation)
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Clinical predictors of adverse outcome in VTE outpatients – the VERITY PUSH (Prospective Follow-Up Survey in Verity Hospitals) study Peter Rose, Aidan.
This material was developed by Oregon Health & Science University, funded by the Department of Health and Human Services, Office of the National Coordinator.
Higher Incidence of Venous Thromboembolism (VTE) in the Outpatient versus Inpatient Setting Among Patients with Cancer in the United States Khorana A et.
Correlation of Hand-Foot Skin Reaction (HFS) with Treatment Efficacy in Pancreatic Cancer (PC) Patients (pts) Treated with Gemcitabine/Capecitabine plus.
Kang Y et al. Proc ASCO 2010;Abstract LBA4007.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.
T-cell activation positively correlates with cell-associated HIV-DNA level in PBMCs in viremic patients with acute or chronic HIV-1 infection Laurence.
1 Pulminiq™ Cyclosporine Inhalation Solution Pulmonary Drug Advisory Committee Meeting June 6, 2005 Statistical Evaluation Statistical Evaluation Jyoti.
Identification of localized rectal cancer (RC) patients (pts) who may NOT require preoperative (preop) chemoradiation (CRT). D. Roda 1, M. Frasson 2, E.
LUNG CANCER IN PATIENTS UNDER 40 YEARS A PROSPECTIVE OBSERVATIONAL MULTICENTER STUDY: GFPC 1001 STUDY Bigay-Gamé L 1, Bota S 2, Greillier L 3, Monnet I.
Erlotinib plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute.
Adjuvant Chemotherapy for Non–Small-Cell Lung Cancer in the Elderly: A Population-Based Study in Ontario, Canada JOURNAL OF CLINICAL ONCOLOGY, VOLUME 30.
Radiological-histological size correlation in triple-negative breast cancer (TNBC) Abstract # 8254 C Thibault 1, M Gosset 2, F Chamming’s 3, M-A Lefrere-Belda.
Sex-specific trends in lung cancer incidence and survival : a population study of cases 호흡기 내과 R3 조주희 Thorax 2011;66: Camilla M T Sagerup,
TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR TREATMENT OF HER2- POSITIVE ADVANCED GASTRIC OR GASTRO-OESOPHAGEAL JUNCTION.
Department of Clinical Radiotherapy, Royal Marsden Hospital, Sutton, Surrey SM2 5PT, UK R4 한재준 1.
Thromboelastography shows Thromboprophylaxis following Caesarean Section need not be continued after 5 days for women at Moderate Risk of Thromboembolism.
Nguyen Ngoc Tu1,2, Marie-Christine Morel-Kopp3, Chris Ward 3, Robert G
UOG Journal Club: June 2017 Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE.
The VERITY Steering Committee
TBCRC (the translational breast cancer research consortium) 005 Prospective study
Waleed Alselwi1, Thomas Coventary2, Faisal Azam1
Table (1):Relation between lymph node and molecular subtypes.
Shortened Coagulation profile in Pregnancy - A Comparative analysis in different trimesters: Retrospective study from a tertiary care centre Bhavika Rishi,
Dr T P E Wells 13 July 2018 Breast SSG Bath
Effect of rivaroxaban on thrombin generation in vivo
Surgical resection of metachronous liver metastases
Presentation transcript:

Service d’Hématologie Biologique Hôpital Tenon, APHP, Paris, France Group Thrombosis and Cancer Cancer Biology and Therapeutics Centre de Recherche Saint-Antoine INSERM U938 Université Pierre et Marie Curie  In patients with lung adenocarcinoma, metastasis, advanced stage and chemotherapy (CTx) are factors which increase the risk of venous thromboembolism (VTE). However, routine pharmacological thromboprophylaxis is not recommended but individualized risk assessment for VTE is encouraged  Lung Adenocarcinoma stands out among the types of cancer with a high risk for VTE, having an adjusted relative risk (RR) ratio of 22 compared with non cancer patients  The development of risk assessment models (RAM) to stratify the risk of VTE adapted for cancer patients and prospective clinical validation is necessary  A multicenter cross-sectional observational study of the Tenon Thrombosis group (COMPASS - Study), identified the most frequent and clinically relevant risk factors for VTE in medical and surgical patients which can be used to create a RAM model adapted to specific patients’ settings The incorporation of biomarkers of blood hypercoagulability int the RAM could improve its sensitivity to identify patients eligible for thromboprophylaxis.  To this aim we conducted an observational prospective study, in patients with lung adenocarcinoma, to investigate the variability of haematological biomarkers (HB) associated with hypercoagulability, with respect to adenocarcinoma-related characteristics Introduction Results The present study evaluated a wide spectrum of biomarkers of cellular and plasma hypercoagulability in patients with lung adenocarcinoma We established that the increase of procoagulant phospholipids in plasma, the up-regulation of TF pathway, the enhanced D-Dimers formation and heparanase release is a universal phenomenon in lung cancer Chemotherapy enhances both cellular and plasma hypercoagulability Variations of thrombin generation and FVIIa levels allow to identify subgroups of patients who present hypercoagulability Baseline values of TGT, PPL, HPA were found to be related with 3-month mortality and the incidence of thrombotic episodes These data allow to propose that the weighted incorporation of biomarkers of cellular and plasma hypercoagulabilty in RAMs for VTE might improve their predictive value. This concept is being studied on an ongoing trial Conclusion Differential Influence of Lung Cancer Stage, Time from Diagnosis and Chemotherapy on Plasma and Cellular Biomarkers of Hypercoagulability. The ROADMAP Study Ilias Evmorfiadis 1,2, Paraskevi Boura 3, Aurélie Rousseau 1,2,4, Ariadni Charpidou 2, Giannis Giozos 2, Patrick Van Dreden 4, Konstantinos Syrigos 2, Anastasia Spanoudaki 5, Matthieu Grusse 4, Ismail Elalamy 1,2 and Grigoris T. Gerotziafas 1,2 1 Service d’Hématologie Biologique Hôpital Tenon, Hôpitaux Universitaires Est Parisien, Assistance Publique Hôpitaux de Paris, Paris, France 2 INSERM U938, Faculté de Médecine Pierre et Marie Curie, Université Paris VI, Paris, France 3 Oncology Unit GPP, 3rd Department of Medicine, Athens School of Medicine, Athens, Greece 4 Research and Development, Diagnostica Stago, Gennevilliers, France Patients and Methods Patients and study design  Patients with documented lung adenocarcinoma eligible for CTx at distance of at least 3 months from surgery or hospitalization were included in the study (n=80). Patients were either CTx naive (n=46) or had already received CTx (n=34). The control group (CG) consisted of 30 healthy age & sex-matched individuals.  Patients were assessed at baseline on the day of their entry in the study, and after 3 months follow- up. HB screening took place at baseline and after 3 cycles of CTx and one month after last CTx or before change of therapy line  Thrombin generation (TGT) in citrated PPP was assessed with the Thrombogram-Thrombinoscope® assay using PPP-reagent®5 pm TF by Diagnostica Stago. The levels of P-Selectin and heparanase (HPA) in plasma were measured with ELISA Kit (Cusabio Biotech and R&D Systems respectively). The procoagulant phospholipids clotting time (PPL) was measured with STA-Procoag-PPL®,levels of Factor VIIa by Staclot VIIa-rTF®, D-Dimers (DDi) by Liatest D-Di (Diagnostica Stago, France), and Tissue Factor activity (TFa) by specific clotting based home test  Patients’ mortality and symptomatic thrombotic events were recorded Figure 1. Baseline hypercoagulability markers in patients (D-Dimers, MRI & Heparanase) according to mortality in the 3 month follow-up period * p<0,05 versus CG $ p<0,05 versus NG  Patients showed significantly shortened PPL and significantly higher levels of TFa, D-Dimer and HPA as compared to the CG. The levels of FVIIa were significantly lower in patients compared to CG  P-Selectin levels and endogenous thrombin potential (ETP) did not differ between the two groups. The chronometric parameters of TGT (lag-time, and ttPeak) were significantly prolonged. The velocity of the propagation phase of TGT (MRI) was significantly lower in patients as compared to CG  The Naive Group of patients (NG) showed significantly shorter lag-time and lower ETP as compared to the On Treatment Group (OTG). The NG showed significantly higher levels of HPA as compared to the OTG (Table I.) Hypercoagulability BiomarkersAll Patients (n=79) NG (n=29) OTG (n=50) CG (n = 30) PPL-ct (sec)27±6*27±7*27,6±7,5*62,8±9 TFa (ng/ml)6.2±4.7*6,2±4*6,6±5,2*0,26±0.1 DD (μg/ml)1,8±2,2*1,1±1*1,4±1,2*0,3±0.01 HPA (ng/ml)0,4±1,2*0,32±0.12 $ *0,23±0,1*0,12±0,02 FVIIa (U/ml)37±20*34±16*34±20*50,9±11 P-Selectin (ng/ml)65,4±2064,8±1562,6±1962,6±10 Lag-time (min)4,3±0,8*3,9±1 $ 4,5±0,9*2,5±0.01 ttPeak (min)7.7±1.4*7±18,7±1,3*5±1 MRI (nM/min)91±40*94±4187,3±33*110±24 Peak (nM)279±71*279±76284±62*288±36 ETP (nM.min)1583± ± ±315* $ 1496±191 Table I. Baseline hypercoagulability markers in patients stratified according to Chemotherapy status (naive or on-treatment) Figure 4. Baseline hypercoagulability markers in patients according to thrombosis in the 3 month follow-up period Figure 3. Baseline hypercoagulability markers in patients according to cancer stage Figure 2. Baseline hypercoagulability markers in patients according to cancer grade  Patients who died within the 3-month follow-up (31%) had higher baseline levels of DDi and lower HPA levels as compared to those who were still alive (Fig. 1)  The increase of TGT, as well as that of HPA, P-Selectin, FVIIa was associated with the grade of the disease (Fig. 2)  Patients with metastatic cancer had higher levels of P-Selectin, TFa, DDi, FVIIa, TGT and HPA as compared to patients with localized or advanced disease (Fig. 3)  Patients who experienced a thrombotic episode (5%) had significantly higher baseline levels of TGT, shorter PPL and lower levels of HPA as compared to those who remained without thrombosis (Fig 4)